Replimune Group (NASDAQ:REPL) Shares Gap Up – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $10.14, but opened at $12.60. Replimune Group shares last traded at $12.39, with a volume of 337,188 shares changing hands.

Analysts Set New Price Targets

A number of analysts have commented on REPL shares. Jefferies Financial Group raised their target price on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. HC Wainwright upped their price target on shares of Replimune Group from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, BMO Capital Markets lifted their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Replimune Group currently has an average rating of “Buy” and an average price target of $19.14.

Replimune Group Price Performance

The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The company has a fifty day moving average of $12.18 and a two-hundred day moving average of $11.28.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. Equities analysts expect that Replimune Group, Inc. will post -2.91 earnings per share for the current year.

Insider Activity at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now directly owns 109,885 shares in the company, valued at $1,184,560.30. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in REPL. Millennium Management LLC lifted its holdings in shares of Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after acquiring an additional 2,656,173 shares during the period. Braidwell LP lifted its holdings in Replimune Group by 203.0% during the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock valued at $33,656,000 after purchasing an additional 2,057,460 shares during the last quarter. State Street Corp boosted its position in Replimune Group by 102.1% in the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after buying an additional 1,182,181 shares in the last quarter. Baker BROS. Advisors LP boosted its position in Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after buying an additional 1,000,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC grew its stake in Replimune Group by 45.5% during the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock worth $8,371,000 after buying an additional 238,747 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.